In patients with Duchenne muscular dystrophy (DMD), progressive cardiac muscle deterioration and cardiomyopathy represent a significant complication requiring early, proactive management alongside other aspects of care.
Cardiac muscle deterioration is a recognized consequence of DMD. Intervening early — before substantial decline in cardiac function — is central to managing cardiomyopathy in this population and can help slow its progression over time.
The protocol centers on early initiation of cardioprotective medication. Timing of treatment start is a key determinant of outcomes. The full structured regimen specifies which agents are applicable and how they are prioritized.
Treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), beta blocker, aldosterone antagonists, and SGLT-2 inhibitors can slow the course of cardiac muscle deterioration in DMD if the medications are started early.
View source ↗